BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

482 related articles for article (PubMed ID: 19585548)

  • 1. High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis.
    Lindor KD; Kowdley KV; Luketic VA; Harrison ME; McCashland T; Befeler AS; Harnois D; Jorgensen R; Petz J; Keach J; Mooney J; Sargeant C; Braaten J; Bernard T; King D; Miceli E; Schmoll J; Hoskin T; Thapa P; Enders F
    Hepatology; 2009 Sep; 50(3):808-14. PubMed ID: 19585548
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association between reduced levels of alkaline phosphatase and survival times of patients with primary sclerosing cholangitis.
    Lindström L; Hultcrantz R; Boberg KM; Friis-Liby I; Bergquist A
    Clin Gastroenterol Hepatol; 2013 Jul; 11(7):841-6. PubMed ID: 23353641
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis.
    Mitchell SA; Bansi DS; Hunt N; Von Bergmann K; Fleming KA; Chapman RW
    Gastroenterology; 2001 Oct; 121(4):900-7. PubMed ID: 11606503
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-dose ursodeoxycholic acid increases risk of adverse outcomes in patients with early stage primary sclerosing cholangitis.
    Imam MH; Sinakos E; Gossard AA; Kowdley KV; Luketic VA; Edwyn Harrison M; McCashland T; Befeler AS; Harnois D; Jorgensen R; Petz J; Keach J; DeCook AC; Enders F; Lindor KD
    Aliment Pharmacol Ther; 2011 Nov; 34(10):1185-92. PubMed ID: 21957881
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bile acid changes after high-dose ursodeoxycholic acid treatment in primary sclerosing cholangitis: Relation to disease progression.
    Sinakos E; Marschall HU; Kowdley KV; Befeler A; Keach J; Lindor K
    Hepatology; 2010 Jul; 52(1):197-203. PubMed ID: 20564380
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metronidazole and ursodeoxycholic acid for primary sclerosing cholangitis: a randomized placebo-controlled trial.
    Färkkilä M; Karvonen AL; Nurmi H; Nuutinen H; Taavitsainen M; Pikkarainen P; Kärkkäinen P
    Hepatology; 2004 Dec; 40(6):1379-86. PubMed ID: 15565569
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Budesonide or prednisone in combination with ursodeoxycholic acid in primary sclerosing cholangitis: a randomized double-blind pilot study. Belgian-Dutch PSC Study Group.
    van Hoogstraten HJ; Vleggaar FP; Boland GJ; van Steenbergen W; Griffioen P; Hop WC; van Hattum J; van Berge Henegouwen GP; Schalm SW; van Buuren HR
    Am J Gastroenterol; 2000 Aug; 95(8):2015-22. PubMed ID: 10950051
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ursodeoxycholic acid therapy for primary sclerosing cholangitis: results of a 2-year randomized controlled trial to evaluate single versus multiple daily doses.
    van Hoogstraten HJ; Wolfhagen FH; van de Meeberg PC; Kuiper H; Nix GA; Becx MC; Hoek AC; van Houte DP; Rijk MC; Salemans JM; Scherpenisse J; Schrijver M; Smit AM; Spoelstra P; Stadhouders PH; Tan TG; Hop WC; ten Kate FJ; vanBerge-Henegouwen GP; Schalm SW; van Buuren HR
    J Hepatol; 1998 Sep; 29(3):417-23. PubMed ID: 9764988
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prospective evaluation of ursodeoxycholic acid withdrawal in patients with primary sclerosing cholangitis.
    Wunsch E; Trottier J; Milkiewicz M; Raszeja-Wyszomirska J; Hirschfield GM; Barbier O; Milkiewicz P
    Hepatology; 2014 Sep; 60(3):931-40. PubMed ID: 24519384
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of curcumin in primary sclerosing cholangitis: an open label pilot study.
    Eaton JE; Nelson KM; Gossard AA; Carey EJ; Tabibian JH; Lindor KD; LaRusso NF
    Scand J Gastroenterol; 2019 May; 54(5):633-639. PubMed ID: 31131678
    [No Abstract]   [Full Text] [Related]  

  • 11. High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis.
    Smith T; Befeler AS
    Curr Gastroenterol Rep; 2007 Mar; 9(1):54-9. PubMed ID: 17335678
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A placebo-controlled randomised trial of budesonide for PBC following an insufficient response to UDCA.
    Hirschfield GM; Beuers U; Kupcinskas L; Ott P; Bergquist A; Färkkilä M; Manns MP; Parés A; Spengler U; Stiess M; Greinwald R; Pröls M; Wendum D; Drebber U; Poupon R
    J Hepatol; 2021 Feb; 74(2):321-329. PubMed ID: 32950590
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-dose ursodeoxycholic acid is associated with the development of colorectal neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis.
    Eaton JE; Silveira MG; Pardi DS; Sinakos E; Kowdley KV; Luketic VA; Harrison ME; McCashland T; Befeler AS; Harnois D; Jorgensen R; Petz J; Lindor KD
    Am J Gastroenterol; 2011 Sep; 106(9):1638-45. PubMed ID: 21556038
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A network meta-analysis of the efficacy and side effects of UDCA-based therapies for primary sclerosing cholangitis.
    Zhu GQ; Shi KQ; Huang GQ; Wang LR; Lin YQ; Braddock M; Chen YP; Zhou MT; Zheng MH
    Oncotarget; 2015 Sep; 6(29):26757-69. PubMed ID: 26378046
    [TBL] [Abstract][Full Text] [Related]  

  • 15. norUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitis.
    Fickert P; Hirschfield GM; Denk G; Marschall HU; Altorjay I; Färkkilä M; Schramm C; Spengler U; Chapman R; Bergquist A; Schrumpf E; Nevens F; Trivedi P; Reiter FP; Tornai I; Halilbasic E; Greinwald R; Pröls M; Manns MP; Trauner M;
    J Hepatol; 2017 Sep; 67(3):549-558. PubMed ID: 28529147
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of inflammatory bowel disease and ursodeoxycholic acid therapy on small-duct primary sclerosing cholangitis.
    Charatcharoenwitthaya P; Angulo P; Enders FB; Lindor KD
    Hepatology; 2008 Jan; 47(1):133-42. PubMed ID: 17992695
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ursodeoxycholic acid and artesunate in the treatment of severe falciparum malaria patients with jaundice.
    Treeprasertsuk S; Silachamroon U; Krudsood S; Huntrup A; Suwannakudt P; Vannaphan S; Wilairatana P
    J Gastroenterol Hepatol; 2010 Feb; 25(2):362-8. PubMed ID: 19817958
    [TBL] [Abstract][Full Text] [Related]  

  • 18.  Alkaline phosphatase normalization is a biomarker of improved survival in primary sclerosing cholangitis.
    Hilscher M; Enders FB; Carey EJ; Lindor KD; Tabibian JH
    Ann Hepatol; 2016; 15(2):246-53. PubMed ID: 26845602
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-dose ursodeoxycholic acid in primary sclerosing cholangitis: a 5-year multicenter, randomized, controlled study.
    Olsson R; Boberg KM; de Muckadell OS; Lindgren S; Hultcrantz R; Folvik G; Bell H; Gangsøy-Kristiansen M; Matre J; Rydning A; Wikman O; Danielsson A; Sandberg-Gertzén H; Ung KA; Eriksson A; Lööf L; Prytz H; Marschall HU; Broomé U
    Gastroenterology; 2005 Nov; 129(5):1464-72. PubMed ID: 16285948
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination Therapy of All-Trans Retinoic Acid With Ursodeoxycholic Acid in Patients With Primary Sclerosing Cholangitis: A Human Pilot Study.
    Assis DN; Abdelghany O; Cai SY; Gossard AA; Eaton JE; Keach JC; Deng Y; Setchell KD; Ciarleglio M; Lindor KD; Boyer JL
    J Clin Gastroenterol; 2017 Feb; 51(2):e11-e16. PubMed ID: 27428727
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.